Drug intelligence / Profile preview

hyaluronic acid + trehalose + NAAGA

Development stage
Phase 3
Lead developer
Théa Pharmaceuticals
Modality
Small Molecules, Peptides
Administration
Ophthalmic
01

Overview

This is a combination ophthalmic formulation containing hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA). Hyaluronic acid acts as a lubricant and moisturizer for the ocular surface, helping to retain water and protect the corneal epithelium. Trehalose is a natural disaccharide with bioprotectant properties that stabilizes cell membranes and protects ocular surface cells from desiccation-induced damage. NAAGA is an anti-inflammatory agent that reduces ocular inflammation by inhibiting inflammatory mediators. The combination aims to provide enhanced hydration, lubrication, cellular protection, and anti-inflammatory effects for patients with moderate-to-severe dry eye disease (DED). Clinical studies suggest this triple-combination improves tear film stability, reduces symptoms of dryness and irritation, decreases inflammation markers on the ocular surface, and increases patient comfort compared to formulations without all three components[2][3].

Brand names
T2769T-2769T 2769
Other names
NAAGA + hyaluronic acid + trehalosetrehalose + hyaluronic acid + N-acetyl-aspartyl-glutamic acidpreservative-free eye drops T2769
02

Targets

NeuraminidaseGRM3 (mGluR3)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on hyaluronic acid + trehalose + NAAGA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyaluronic acid + trehalose + NAAGA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call